In addition to improvements in LFTs [ALT: 94 (47–122) vs. 39 (31–49) IU/L; p< 0.0001, AST: 89 (43–114) vs. 37 (30–47) U/L; p< 0.0001] and LSM: 8.4 (7.1–9.3) vs. 7.5 (6.4–8.4) kPa; p = 0.0261], a significant reduction in liver steatosis was also observed [CAP 335 (281–392) vs. 256 (212–299) dB/m; p = 0.0076] [124]. The gene discussed is GPT; the disease is fatty liver disease.